L-NIL

Drug Profile

L-NIL

Alternative Names: N-iminoethyl-L-lysine

Latest Information Update: 02 Aug 2002

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Class Antirheumatics
  • Mechanism of Action Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammation; Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 05 Apr 2000 Monsanto has merged with Pharmacia & Upjohn to form Pharmacia Corporation
  • 07 Dec 1999 A study in a preclinical model of osteoarthritis has been added to the pharmacodynamics section
  • 01 Sep 1998 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top